Brief: Matinas Biopharma Announces Initiation Of Enhance-It Study Of Mat9001 Against Vascepa
05/03/2020 12:21
March 5 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA ANNOUNCES INITIATION OF ENHANCE-IT STUDY
OF
MAT9001 AGAINST VASCEPA®
* MATINAS BIOPHARMA HOLDINGS INC - TOPLINE DATA EXPECTED Q4
2020
Source text for Eikon: ID:nGNX3pQWxW
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing